Kiniksa Pharmaceuticals International earnings release, October 27, 2026

KNSA · 2026-10-27 07:32 BMO ET · 8-K on SEC

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses not stated in the 8-K
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

not stated in the 8-K

Guidance

not stated in the 8-K

What drove it

  • Revenue story not stated in the 8-K
  • EPS story not stated in the 8-K
  • One-off check not stated in the 8-K

The good

  • none

The bad

  • none

The ugly

  • none

Open questions

  • none
Full release

Earnings: KNSA — filed 2026-10-27

Kiniksa Pharmaceuticals International, plc (KNSA) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

​

​

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST®

(rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – ​

London – October 27, 2026 – Kiniksa Pharmaceuticals International, plc

(Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution.

“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year,” s aid Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa. “Our robust financial position supports continued investment in value creation through ARCALYST, KPL-387, and KPL-1161. We now expect 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from our previous range of between $980 and $995 million. Additionally, we continue to enroll and dose patients in PASTORALE, the pivotal Phase 3 trial of KPL-387 evaluating once monthly subcutaneous dosing. We expect data in the second half of 2027, with the goal of bringing this important treatment option to patients in the 2028/2029 timeframe. We remain on track to initiate a Phase 1 trial of KPL-1161 by the end of this year.”

​

Portfolio Execution

ARCALYST (IL-1α and IL-1β cytokine trap)

● ARCALYST net product revenue was $286.0 million for the third quarter of 2026.

● As of the end of the third quarter of 2026, approximately 23% of the 14,000 annual multiple-recurrence patients were actively on ARCALYST treatment.

● Since launch, more than 5,450 prescribers have written ARCALYST prescriptions for recurrent pericarditis.¹

​

KPL-387 (monoclonal antibody IL-1 receptor antagonist)

​

KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist)

​

Financial Results

​

Financial Guidance²

​

Conference Call Information

​

About Kiniksa

Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

​

About ARCALYST

ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the

U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

​

IMPORTANT SAFETY INFORMATION ABOUT ARCALYST³

​

For more information about ARCALYST, talk to your doctor and see the

Product Information.

​

About KPL-387

KPL-387 is an independently developed, investigational, fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling of the cytokines IL-1α and IL-1β. Kiniksa believes KPL-387 could expand the treatment options for recurrent pericarditis patients by potentially enabling dosing with a single monthly SC self-injection in a liquid formulation. In October 2025, the FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis.

​

About PASTORALE

PASTORALE is a double-blind, placebo controlled, randomized withdrawal (RW) study enrolling up to approximately 85 patients with recurrent pericarditis. In the first period, a single-blind run-in (RI), all participants will receive KPL-387 while conventional oral pericarditis medications are weaned and discontinued. Participants achieving Clinical Response in the RI period will then be randomized in a 1:1 ratio to receive either KPL-387 300 mg SC once-monthly or placebo in an event-driven, double-blind, RW period. The primary efficacy endpoint is time to first-adjudicated pericarditis recurrence during the RW period. Participants in the RW period may be eligible to enter a long-term extension.

​

About KPL-1161

KPL-1161 is an independently developed, investigational, Fc-modified IgG2 monoclonal antibody that binds IL-1R1, inhibiting the signaling of the cytokines IL-1α and IL-1β, with a target profile of quarterly SC dosing. Kiniksa is currently engaging in preclinical development activities for KPL-1161.⁴

​

Financial statements

Income Statement

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC — jkirshenbaum@kiniksa.com (In thousands, except share and per share amounts)

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SELECTED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Three Months Ended – September 30, – 2026KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SELECTED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Three Months Ended – September 30, – 2025KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SELECTED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Nine Months Ended – September 30, – 2026KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SELECTED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Nine Months Ended – September 30, – 2025
Revenue:Product revenue, net285,970180,855743,836475,437
Revenue:Total revenue285,970180,855743,836475,437
Costs and operating expenses:Cost of goods sold27,75920,25772,12756,728
Costs and operating expenses:Collaboration expenses105,82863,307269,474159,515
Costs and operating expenses:Research and development32,78624,166101,16062,244
Costs and operating expenses:Selling, general and administrative65,36149,104190,378139,497
Costs and operating expenses:Total operating expenses231,734156,834633,139417,984
Costs and operating expenses:Income from operations54,23624,021110,69757,453
Costs and operating expenses:Other income, net4,8213,13612,1868,146
Costs and operating expenses:Income before income taxes59,05727,157122,88365,599
Costs and operating expenses:Provision for income taxes-11,712-8,722-27,514-20,793
Costs and operating expenses:Net income47,34518,43595,36944,806
Costs and operating expenses:Net income per share attributable to ordinary shareholders—basic0.610.251.230.61
Costs and operating expenses:Net income per share attributable to ordinary shareholders—diluted0.560.231.140.57
Costs and operating expenses:Weighted average ordinary shares outstanding—basic78,192,60374,714,84677,435,07773,605,690
Costs and operating expenses:Weighted average ordinary shares outstanding—diluted84,920,06080,035,40083,713,01578,027,370

Balance Sheet

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC — jkirshenbaum@kiniksa.com (in thousands)

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA – (Unaudited) – As of – June 30, – 2026KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA – (Unaudited) – As of – December 31, – 2025
Cash, cash equivalents, and short-term investments568,758414,074
Working capital558,244387,993
Total assets983,243763,633
Accumulated deficit-366,769-462,138
Total shareholders' equity710,193567,606

Forward-Looking Statements... (truncated)looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST will achieve blockbuster status in 2026 with net product revenue between $1.045 billion and $1.050 billion; our expectation to have data from our pivotal Phase 3 trial of KPL-387 in recurrent pericarditis in the second half of 2027; our expectation to begin commercialization of KPL-387 in 2028 or 2029; our belief that we are on track to initiate a Phase 1 first-in-human clinical trial of KPL-1161 by the end of 2026; the target profiles for our product candidates, including a once-monthly subcutaneous dosing profile for KPL-387 and a once-quarterly subcutaneous dosing profile for KPL-1161; our expectations that 2026 annual R&D expenses will be between $160 million and $170 million and that 2026 annual SG&A expenses will be between $270 million and $280 million; our expectation that our current operating plan will remain cash flow positive on an annual basis; our beliefs about the mechanisms of our assets and potential impact of their approach; statements regarding our belief about the future of our commercial opportunities; and our belief that our portfolio of assets offers the potential for differentiation.

​

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials, including the data from our ongoing clinical trials of KPL-387 in recurrent pericarditis; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; business development activities and⁵ their impact on our financial performance and strategy; changes in our operating plan, business development strategy or funding requirements; existing or new competition; current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; and the impact of global economic policy, including any uncertainty in national and international markets.

​

These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

​

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!®

Kiniksa Investor & Media Contact

Jonathan Kirshenbaum

(781) 829-3949 jkirshenbaum@kiniksa.com

​

​⁶

​

​

​

​⁷

​⁸

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Kiniksa Pharmaceuticals International earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.